Registry of Cardiovascular Disease Patients (CVD Registry)

Maccabi Healthcare Services, Israel

Status: Invitation-only

Conditions: Ischemic Heart Disease; Atrial Fibrillation; Cerebrovascular Atherosclerosis; Peripheral Vascular Disease; Cerebrovascular Disease; Congestive Heart Failure

Study type: Observational

Funder types: Other

Identifiers

NCT01759225

MACCVREG1

cvdregistry (Registry Identifier)

Details and patient eligibility

About

A computerized registry of cardiovascular disease patients in a large health maintenance organization in Israel. The registry is aimed to be used by health professionals to identify cardiovascular disease patients and to follow the courses of their illnesses and risk factors.

Full description

The registry was initiated in 1998 by Maccabi Healthcare services, which is the second largest publicly funded HMO in Israel,serving 24% of the total population with a nationwide distribution.

The registry uses advanced information technology that integrates personal computerized community and hospital records, data from laboratory tests, dispensed medications, physiological signals, radiological images, and reports from investigations and procedures.

Enrollment: 110,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical Diagnosis of the following:

Ischemic Heart Disease,MI,non-MI,congestive heart failure,peripheral vascular disease, cerebrovascular disease CVA,TIA,patients with first AMI diagnosis from community physicians if they were hospitalized for lasting at least 3 days during a 30-day period prior to diagnosis.

• Patients with prior coronary artery bypass grafting(CABG) or percutaneous coronary intervention (PCI), using relevant Current Procedural Terminology (CPT) codes

Exclusion criteria

• patients who were diagnosed as suffering from CHD by primary physician or general hospitals prior to 2000 with no further indication
• Patients whose primary physician reported that the patient is CHD-free providing adequate medical records

Trial design

110,000 participants in 1 patient group

Cardiovascular Disease Patients